Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

A potential approval of Kisqali will provide an effective and ... $1.3 billion in the first half of 2024. Last year, the FDA also expanded Eli Lilly’s LLY Verzenio’s (abemaciclib) indication.

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL ...